Talazoparib
Talazoparib is a pharmaceutical drug with 84 clinical trials. Currently 29 active trials ongoing. Historical success rate of 74.4%.
Success Metrics
Based on 32 completed trials
Phase Distribution
Phase Distribution
38
Early Stage
39
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
66.7%
32 of 48 finished
33.3%
16 ended early
29
trials recruiting
84
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
Clinical Trials (84)
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors
Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes
A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer
Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 84